|
Non-Small Cell Lung Carcinoma
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients.
|
28971587 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
|
22919003 |
2012 |
|
Bacterial Infections
|
0.200 |
Biomarker
|
group |
RGD |
Role of Syndecan-4 in the cellular invasion of Orientia tsutsugamushi.
|
15001228 |
2004 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Besides, si-β-catenin was observed to inhibit the promotion of PTC cell migration and invasion caused by SDC4 overexpression.
|
30165731 |
2018 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In Sdc4-/- mice, colitis-like symptoms including severe weight loss, shortened colon length, histological damage, and invasion of macrophages and granulocytes were markedly aggravated compared with wild type (WT) animals.
|
30053064 |
2018 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Global important changes in cell adhesion receptors, which include integrins and syndecan-4 triggered by IGF-IR inhibition, regulate adhesion and invasion.
|
28079144 |
2017 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells.
|
19632304 |
2009 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The fact that reducing SDC-4 expression by RNA interference decreased SDF-1-induced Huh7 hepatoma cell migration and invasion strongly indicates that SDC-4 may be an auxiliary receptor for SDF-1.
|
17259344 |
2007 |
|
Degenerative polyarthritis
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
This study revealed that the cartilage protective effect of osthole in a MIA-induced osteoarthritis (OA) murine model can be explained by downregulation of COX-2 and RUNX2 by inhibition of NF-κB and HIF-2α up-regulated by OA induction, resulting in downregulation of MMP-13, Syndecan IV and ADAMTS-5.
|
31765607 |
2020 |
|
Degenerative polyarthritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Using an immunoassay for the extracellular domain of syndecan-4, we found 68% of the syndecan-4 in the culture supernatant of OA chondrocytes culture, suggesting that a large majority of the syndecan-4 is shed and released in the extracellular medium.
|
31455087 |
2019 |
|
Heart failure
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Increased syndecan-4 levels were previously detected after acute myocardial infarction and in subjects with heart failure.
|
29232393 |
2017 |
|
Heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our data suggest that syndecan-4 is essential for the compensated hypertrophy and the maintenance of cardiac function during the process of heart failure following pressure overload.
|
28395201 |
2017 |
|
Congestive heart failure
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Increased syndecan-4 levels were previously detected after acute myocardial infarction and in subjects with heart failure.
|
29232393 |
2017 |
|
Congestive heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our data suggest that syndecan-4 is essential for the compensated hypertrophy and the maintenance of cardiac function during the process of heart failure following pressure overload.
|
28395201 |
2017 |
|
Heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological and molecular consequences associated with syndecan-4 shedding remain poorly understood.
|
26449522 |
2015 |
|
Congestive heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological and molecular consequences associated with syndecan-4 shedding remain poorly understood.
|
26449522 |
2015 |
|
Degenerative polyarthritis
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Both VEGF and syndecan-4 are expressed by chondrocytes and both are involved in the regulation of matrix metalloproteinase-3, resulting in the activation of aggrecanase II (ADAMTS-5), which is essential in the pathogenesis of OA.
|
25274915 |
2014 |
|
Heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Syndecan-4, a transmembrane heparan sulfate proteoglycan, is essential for pathological remodeling, and we here investigated its expression and shedding during heart failure.
|
23374111 |
2013 |
|
Congestive heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Syndecan-4, a transmembrane heparan sulfate proteoglycan, is essential for pathological remodeling, and we here investigated its expression and shedding during heart failure.
|
23374111 |
2013 |
|
Degenerative polyarthritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our data suggest that strategies aimed at the inhibition of syndecan-4 will be of great value for the treatment of cartilage damage in osteoarthritis.
|
19684582 |
2009 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We demonstrated here, that among all cell surface heparan-sulfate proteoglycans, syndecan-4 (SDC4) was essential for cancer cell interaction with ATXβ but was restrained by heparan-sulfate chains.
|
30237860 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
We demonstrated here, that among all cell surface heparan-sulfate proteoglycans, syndecan-4 (SDC4) was essential for cancer cell interaction with ATXβ but was restrained by heparan-sulfate chains.
|
30237860 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings indicate the genetic importance of DC heparan sulfate proteoglycans in tumor growth and may guide therapeutic development of novel strategies to target syndecan-4 and heparan sulfate in cancer.
|
27237321 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings indicate the genetic importance of DC heparan sulfate proteoglycans in tumor growth and may guide therapeutic development of novel strategies to target syndecan-4 and heparan sulfate in cancer.
|
27237321 |
2016 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Cell surface heparan sulfate proteoglycans (HSPGs) are principal mediators of cancer cell properties and the E2-ER pathway as well as those activated by EGFR and IGFR have significant roles in regulating the expression of certain cell surface HSPGs, such as syndecan-2 (SDC-2), syndecan-4 (SDC-4) and glypican-1.
|
23374155 |
2013 |